CJC-1295 (No DAC) / Ipamorelin

10 mg GHRH/GHRP research blend

What Is This?

This blend pairs CJC-1295 (a growth-hormone-releasing hormone analog) with Ipamorelin (a selective ghrelin receptor agonist). Together they form the standard research combination for studying how the pituitary gland releases growth hormone in pulses - like the body does naturally.

What's In the Vial

What Do Researchers Study?

CJC-1295 stimulates the GHRH receptor with a short half-life suited for pulse-pattern research in pituitary cell cultures. Ipamorelin adds ghrelin receptor activation with minimal impact on cortisol and prolactin pathways - a selectivity that distinguishes it from older GHRP compounds. Together they are the standard in vitro combo for studying growth hormone axis signaling.

Common Research Uses

What the Science Is Looking At

How It Works - In Plain English

GHRH Stimulation

CJC-1295 (no DAC) activates GHRH receptors with a short half-life - suited for studying pulse-pattern hormone release rather than flat, continuous elevation.

Selective GHRP

Ipamorelin stimulates the ghrelin receptor with minimal cortisol or prolactin side effects compared to older GHRP compounds like GHRP-6.

Synergy

Combined use produces stronger GH release in pituitary cell models than either peptide alone - a synergy researchers quantify with GH ELISA readouts.

Downstream IGF-1

Growth hormone released in culture triggers IGF-1 production in liver cell models - letting labs trace the full axis from pituitary to hepatocyte in one workflow.

Product Specifications

Total content10 mg per vial (5 mg each)
FormLyophilized powder
Purity99%+ (HPLC)
Storage-20 C

Order CJC / Ipamorelin

99%+ Purity • Third-Party Tested • COA Included • Ships Canada 1-2 Days

Multi-vial deal: 2+ vials of this peptide = $10 off per vial!

Browse All Research Peptides

💬